← Back to Search

Cholinergic Agonist

Pilocarpine 2% Ophthalmic Spray for Presbyopia (VISION-2 Trial)

Phase 3
Waitlist Available
Research Sponsored by Eyenovia Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 120 minutes post-dosing
Awards & highlights

VISION-2 Trial Summary

This study is evaluating whether a treatment for glaucoma is safe and effective.

VISION-2 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~120 minutes post-dosing
This trial's timeline: 3 weeks for screening, Varies for treatment, and 120 minutes post-dosing for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of subjects gaining ≥ 15 letters in mesopic, high contrast, binocular distance corrected near visual acuity (DCNVA) with ≤ 5 letter loss in mesopic, high contrast, binocular distance visual acuity (DVA)

VISION-2 Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Pilocarpine 2% Ophthalmic SprayExperimental Treatment1 Intervention
2% pilocarpine ophthalmic spray administered with the Optejet dispenser
Group II: Placebo SprayPlacebo Group1 Intervention
Placebo ophthalmic spray administered with the Optejet dispenser
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pilocarpine Ophthalmic administered with the Optejet dispenser
2021
Completed Phase 3
~150

Find a Location

Who is running the clinical trial?

Eyenovia Inc.Lead Sponsor
8 Previous Clinical Trials
782 Total Patients Enrolled
1 Trials studying Presbyopia
84 Patients Enrolled for Presbyopia
Tsontcho (Sean) Ianchulev, MD, MPHStudy ChairEyenovia Inc.
3 Previous Clinical Trials
811 Total Patients Enrolled
1 Trials studying Presbyopia
84 Patients Enrolled for Presbyopia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Illinois
How old are they?
18 - 65
What site did they apply to?
VISION-2 Study Site #56
What portion of applicants met pre-screening criteria?
Met criteria

How responsive is this trial?

Typically responds via
Email
Recent research and studies
clinicaltrials.govStudy
Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults
2021. "Safety & Efficacy of Pilocarpine Ophthalmic Spray for Temporary Improvement of Near Vision in Presbyopic Adults". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05114486.
~42 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top